Keyphrases
Atopic Dermatitis
100%
Topical Immunomodulators
100%
Topical Corticosteroids
46%
Adverse Effects
15%
Tacrolimus
15%
Pharmacoeconomics
15%
Pimecrolimus
15%
Quality of Life
7%
Therapeutic Potential
7%
Patient Well-being
7%
Clinical Data
7%
Disease States
7%
Pediatric Population
7%
Pediatric Patients
7%
Economic Burden
7%
Inflammatory Skin Diseases
7%
Topical Administration
7%
First-line Therapy
7%
Quality of Life Impact
7%
Drug Class
7%
Efficacy Data
7%
Antihistamines
7%
Global Prevalence
7%
Skin Care
7%
Healthcare Avoidance
7%
Incremental Cost
7%
Economic Study
7%
Dry Skin
7%
Pimecrolimus Cream
7%
Immunomodulatory Drugs (IMiDs)
7%
Tacrolimus Ointment
7%
Cost-utility
7%
Cost-effectiveness Comparison
7%
Pharmacology, Toxicology and Pharmaceutical Science
Immunomodulating Agent
100%
Atopic Dermatitis
100%
Topical Corticosteroid
46%
Tacrolimus
23%
Pimecrolimus
23%
Pharmacoeconomics
15%
Adverse Event
15%
Prevalence
7%
Dermatitis
7%
Antiinfective Agent
7%
Antihistaminic Agent
7%
Dry Skin
7%
Disease
7%